Infinium Pharmachem Ltd

As of November 18, 2025, Infinium Pharma is fairly valued with a PE ratio of 45.72 and an EV to EBITDA ratio of 24.71, but its year-to-date return of -17.14% indicates underperformance compared to the Sensex's 9.58% gain, suggesting it may not be an attractive investment opportunity.

As of November 17, 2025, Infinium Pharma is considered undervalued with a PE ratio of 44.28 and a favorable PEG ratio of 0.00, indicating attractive growth potential compared to peers, despite a year-to-date return of -19.74%.

As of 17-Nov, Infinium Pharmachem Ltd's stock price is at 240.70, down 3.76%, and has underperformed its sector by 4.04%. The stock is trading below all key moving averages, with a significant decline in investor participation and a year-to-date decline of 19.74%, indicating a persistent downward trend amidst a generally positive market.

Infinium Pharma has demonstrated consistent growth in net sales, increasing from 99.12 Cr in March 2022 to 155.71 Cr in March 2025, but faced profitability challenges in the latest fiscal year, with profit after tax declining from 11.50 Cr in March 2024 to 7.84 Cr in March 2025. Total assets rose significantly, while cash flow from operating activities turned negative in March 2025.

As of 11-Nov, Infinium Pharmachem Ltd is currently priced at 269.40, reflecting a 3.62% increase. Despite recent gains, the stock has negative year-to-date and one-year returns, underperforming the broader market.

As of October 6, 2025, Infinium Pharma is considered very expensive and overvalued with a PE ratio of 45.35 and an EV to EBITDA of 26.13, significantly higher than its peers like Sun Pharma and Cipla, while also underperforming with a year-to-date stock return of -17.81%.

As of September 24, 2025, Infinium Pharma's valuation has shifted to fair with a PE ratio of 46.46, underperforming the Sensex with a year-to-date return of -15.81%, indicating challenges in justifying its current price level despite being fairly valued compared to peers.

As of 24-Sep, Infinium Pharmachem Ltd's stock price is at 252.50, down 0.39%. The stock is underperforming compared to the broader market, with significant declines over various time frames, including a year-to-date drop of 15.81%.

As of September 23, 2025, Infinium Pharma is considered undervalued with an attractive valuation grade, reflected in its strong financial ratios despite a year-to-date stock decline of -15.47% compared to the Sensex's 6.45% return.

As of 23-Sep, Infinium Pharmachem Ltd's stock price is 253.50, down 0.16%. The stock has shown mixed performance, with a recent slight increase but significant declines over the past month and year, indicating underlying challenges despite increased trading activity.

As of 22-Sep, Infinium Pharmachem Ltd's stock price is 253.90, up 2.23% today, but it has a year-to-date decline of 15.34%. Despite outperforming its sector today, the stock's longer-term performance is weak, and decreasing delivery volume suggests waning investor confidence.

As of 19-Sep, Infinium Pharmachem Ltd's stock price is at 248.35, down 0.64%, and has underperformed its sector and the broader market significantly, with a year-to-date decline of 17.19%. Despite this, there has been a 150% increase in delivery volume, indicating some investor interest.

As of 18-Sep, Infinium Pharmachem Ltd's stock price is at 249.95, down 2.36%, and has underperformed its sector by 3.41%. The stock is trading below all key moving averages and has seen a significant drop in investor participation, with a year-to-date decline of 16.66%, contrasting with the Sensex's gain of 7.52%.

As of 17-Sep, Infinium Pharmachem Ltd's stock price is 256.00, up 1.19%, but has underperformed with a year-to-date decline of 14.64% compared to the Sensex's 7.13% gain. The stock is trading below key moving averages and experiencing a significant drop in investor participation, indicating challenges in maintaining upward momentum.

As of September 16, 2025, Infinium Pharma is fairly valued with a PE ratio of 46.55, but it appears overvalued compared to peers like Cipla and Dr. Reddy's Labs, and has underperformed the Sensex with a year-to-date return of -15.64%.

As of 16-Sep, Infinium Pharmachem Ltd's stock price is at 253.00, up 2.85%, but it has underperformed year-to-date with a decline of 15.64% compared to a 28.43% increase over the past year. Despite a positive daily movement, investor participation has decreased significantly, and the stock's performance remains weaker than the benchmark Sensex.

As of September 15, 2025, Infinium Pharma is considered an attractive investment due to its undervaluation compared to peers, strong operational efficiency indicated by a PE ratio of 45.26 and ROCE of 21.16%, despite recent stock performance trailing the Sensex.

As of 15-Sep, Infinium Pharmachem Ltd's stock price is 246.00, down 1.84%, and has significantly underperformed its sector and the broader market. The stock has seen a notable drop in investor participation and has declined 17.97% year-to-date, contrasting with the Sensex's gain of 6.02%.

As of 12-Sep, Infinium Pharmachem Ltd's stock price is at 250.60, down 1.67%, and has underperformed its sector and the broader market. Despite a positive one-year return of 30.22%, recent declines and reduced investor participation indicate ongoing challenges for the stock.